Study on JNJ-56021927 and Abiraterone in Metastatic Prostate Cancer
The study aims to evaluate drug-drug interactions and safety of JNJ-56021927 with abiraterone acetate and prednisone.
Company
Pharmaceutical intelligence for Aragon Pharmaceuticals, Inc. with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.